Drug discovery is evolving rapidly, but successful AI adoption requires more than powerful models. It demands validated evidence, robust governance, and realistic expectations. MadeAi empowers life sciences teams to accelerate drug discovery with AI-powered evidence synthesis and expert human validation, delivering faster scientific insights while maintaining transparency, traceability, and regulatory-grade quality.  Download Deploying AI in…

Drug repurposing has the potential to deliver new therapies faster and at a fraction of the cost of traditional drug development. However, identifying meaningful opportunities remains difficult, with valuable signals often hidden across thousands of research publications. MadeAi combines AI-powered literature review with expert human validation to accelerate evidence synthesis while maintaining transparency, accuracy, and…

AI adoption in evidence synthesis often stalls when traceability, governance, and real-world validation requirements enter the picture. Most evaluations still focus on isolated models instead of the full systems used in regulated workflows. MadeAi embeds human validation, workflow orchestration, auditability, and governance into every stage of evidence synthesis helping organizations move toward defensible, production-ready AI…

AI adoption in life sciences keeps stalling at the same point when compliance, traceability, and validation requirements enter the room. Most pilots never make it to regulatory or payer decision-making. MadeAi is built for exactly that gap. By embedding governance, auditability, and human validation into every workflow, HEOR, Market Access, and Medical Affairs teams can…

Developing Global Value Dossiers (GVDs) is one of the most complex and time-consuming steps in the market access process. Medical Affairs, HEOR, and Regulatory teams must synthesize large volumes of clinical, economic, and real-world evidence while meeting the requirements of multiple HTA bodies across global markets. MadeAi delivers AI-powered GVD automation designed for life…

In highly regulated life sciences environments, AI adoption is often delayed due to compliance, data security, and ownership concerns. MadeAi addresses these challenges by delivering compliant, auditable AI solutions through a structured Build–Operate–Transfer approach that ensures long-term ownership and control. The Build–Operate–Transfer (BOT) model supports phased AI adoption by collaboratively developing compliant solutions and validating them…